Drug Device Combination Products Market Size & Share 2024 - 2032

Drug Device Combination Products Market Size

Drug Device Combination Products Market was valued at around USD 134 billion in 2023 and is projected to observe around 7.8% CAGR from 2024 to 2032. Drug-device combination products are therapeutic or diagnostic products that combine a drug, biological, or biotechnological substance with a medical device. These products are designed to deliver drugs or biological substances to patients through various routes of administration, such as oral, transdermal, inhalation, or implantation, using specialized medical devices.

Continuous advancements in both drug and medical device technologies drive innovation in drug-device combination products. New materials, manufacturing processes, and delivery mechanisms enable the development of more efficient, precise, and patient-friendly products. The increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, respiratory disorders, and cancer drives the demand for innovative treatment options, including drug-device combination products. These products provide effective and targeted therapies for managing chronic conditions.

Furthermore, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines and pathways for the approval and marketing of drug-device combination products. Clear regulatory pathways and support for innovation encourage investment and development in this sector.
 

Drug Device Combination Products Market Trends

• Continued advancements in both drug and medical device technologies are driving innovation in drug-device combination products. This includes the development of novel materials, improved delivery mechanisms, and enhanced connectivity features to improve patient outcomes and treatment efficacy.
   
• Furthermore, there is a growing focus on personalized medicine, driven by advances in genomics, biomarkers, and targeted therapies. Drug-device combination products enable more precise and tailored treatment approaches, allowing for individualized therapy management based on patient-specific characteristics and needs.
   
• Additionally, the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders is fueling the demand for innovative treatment options. Drug-device combination products offer effective and targeted therapies for managing chronic conditions, improving patient outcomes, and reducing healthcare costs.
   

Drug Device Combination Products Market Analysis

Based on product, the market is segmented into drug-eluting stents, infusion pumps, photodynamic therapy, wound care combination product, prefilled syringes, drug-eluting balloons, nebulizers, inhalers, transdermal delivery systems, orthopedic combination products, antimicrobial catheters, and other products. The transdermal delivery systems segment is forecasted to reach USD 63.2 billion by 2032.
 

• Transdermal delivery systems offer a convenient and non-invasive route of drug administration, which can improve patient compliance, particularly for individuals who dislike injections or have difficulty swallowing oral medications. The ease of use and reduced burden of treatment contribute to patient preference for transdermal patches and other delivery systems.
   
• The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and pain-related conditions necessitates effective and convenient treatment options. Transdermal delivery systems provide a continuous and controlled release of medications, making them suitable for managing chronic conditions and improving patient outcomes.
   
• Furthermore, ongoing advancements in drug formulation and delivery technology enable the development of transdermal delivery systems for a wide range of drugs, including small molecules, biologics, and peptides. Innovations in patch design, permeation enhancers, and microneedle technologies enhance drug absorption through the skin, expanding the therapeutic possibilities of transdermal delivery. These factors are expected to boost the segment growth over the forecast period.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the drug device combination products market is segmented into diabetes, cardiovascular disorders, respiratory problems, cancer treatment, antimicrobial application, and other applications. The diabetes segment accounted for USD 43.5 billion in 2023.
 

• The increasing prevalence of diabetes globally, particularly type 2 diabetes, is a significant driver for the development and adoption of drug-device combination products. With millions of individuals requiring daily management of their blood glucose levels, there is a high demand for innovative solutions that can improve diabetes management and outcomes.
   
• Furthermore, ongoing advancements in both drug and medical device technologies drive innovation in drug-device combination products for diabetes. These advancements enable the development of more sophisticated and user-friendly products, such as insulin pumps, continuous glucose monitoring (CGM) systems, and closed-loop systems, which offer improved accuracy, convenience, and control over blood glucose levels. These factors are expected to significantly boost the diabetes segment growth over the forecast period.
   

Based on end-use, the drug device combination products market is segmented into hospitals and clinics, ambulatory surgical centers, home care settings, and other end-users. The hospitals and clinics segment was worth over USD 58.6 billion in 2023.
 

• Hospitals and clinics prioritize the adoption of drug-device combination products that have demonstrated clinical effectiveness and positive patient outcomes. These products offer advanced treatment options that improve disease management, enhance patient care, and contribute to better overall health outcomes, leading to increased adoption in clinical settings.
   
• Additionally, ongoing advancements in both drug and medical device technologies drive innovation in drug-device combination products, making them more effective, reliable, and user-friendly. Hospitals and clinics are keen to adopt innovative solutions that incorporate the latest technological advancements to improve patient care, streamline workflows, and enhance clinical outcomes. These factors are anticipated to propel the growth of the ambulatory surgical centers segment.
   

The U.S. drug device combination products market is forecasted to reach USD 81 billion by 2032, driven by a combination of technological advancements, regulatory compliance, patient safety concerns, and operational efficiency needs.
 

• The regulatory environment established by the U.S. Food and Drug Administration (FDA) plays a significant role in shaping the market for drug-device combination products. The FDA provides specific guidelines and pathways for the approval and marketing of these products, ensuring their safety, efficacy, and quality. Clear regulatory pathways and support for innovation encourage investment and development in this sector.
   
• Furthermore, the increasing prevalence of chronic diseases in the U.S., such as diabetes, cardiovascular diseases, and respiratory disorders, fuels the demand for innovative treatment options. Drug-device combination products offer effective and targeted therapies for managing chronic conditions, improving patient outcomes, and reducing healthcare costs. As the burden of chronic diseases continues to rise, there is a growing need for advanced therapeutic solutions to address these health challenges.
   

The drug device combination products market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• Healthcare policy initiatives and funding decisions in the UK, such as those by the National Institute for Health and Care Excellence (NICE) and the NHS, influence the adoption and reimbursement of drug-device combination products. Products that demonstrate clinical and cost-effectiveness are more likely to receive favorable recommendations and reimbursement from healthcare authorities, driving their adoption in clinical practice. Companies must align their product development strategies with healthcare policy priorities and funding requirements to succeed in the UK market.
   
• Additionally, healthcare systems and payers in the UK are under pressure to contain costs while improving patient outcomes. Drug-device combination products that demonstrate improved clinical outcomes, reduced hospitalizations, and enhanced patient satisfaction are well-positioned to succeed in this environment. Products that offer cost-effective solutions for managing chronic conditions and reducing healthcare utilization are increasingly valued by healthcare providers and payers alike. These factors are expected to boost segment growth over the forecast period.
   

Japan drug device combination products market is anticipated to witness lucrative growth between 2024 to 2032.
 

• Japan has one of the most rapidly aging populations globally, leading to an increased prevalence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders. This demographic trend fuels the demand for innovative treatment options, including drug-device combination products, which offer effective and targeted therapies for managing chronic conditions, improving patient outcomes, and reducing healthcare costs.
   
• Furthermore, there is a growing emphasis on patient-centered care in the Japanese healthcare system, with a focus on improving patient experience, adherence, and outcomes. Drug-device combination products that offer convenience, ease of use, and improved quality of life are increasingly favored by patients and healthcare providers alike. Products that empower patients to better manage their health conditions, such as mobile apps for data analysis and decision support, are highly valued in the market.
   

The drug device combination products market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The Saudi Arabian government has been investing heavily in its healthcare infrastructure and initiatives to enhance the quality and accessibility of healthcare services in the country. These investments drive the adoption of advanced medical technologies, including drug-device combination products, to improve patient care and outcomes.
   
• Additionally, Saudi Arabia is experiencing an increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders. This demographic shift fuels the demand for innovative treatment options, including drug-device combination products, which offer effective and targeted therapies for managing chronic conditions and reducing disease burden. These factors are expected to boost the market growth in the region.
   

Drug Device Combination Products Market Share

The global market for drug device combination products is highly competitive, driven by rapid evolution and innovation. With the global market expanding to meet the needs of an aging population and rising chronic disease burdens, companies vie for market share by leveraging technological advancements, regulatory compliance, and strategic collaborations. Established players continuously invest in research and development to enhance their product portfolios, while emerging entrants disrupt traditional models with novel solutions. Regulatory approvals and adherence to quality standards are paramount, driving companies to demonstrate safety, efficacy, and compliance to gain market acceptance. Partnerships and mergers facilitate access to complementary expertise and resources, accelerating product development and market penetration. Additionally, pricing strategies, reimbursement models, and market access policies significantly influence competitive dynamics.
 

Drug Device Combination Products Market Companies

Key participants operating in the drug device combination products industry include:

• Abbott Laboratories
• AbbVie, Inc.
• Alcon, Inc.
• Bausch Health Companies Inc
• Baxter International Inc.
• Bayer AG
• Becton, Dickinson and Company
• Boston Scientific Corporation
• GlaxoSmithKline plc
• Johnson & Johnson
• Kaleo, Inc.
• Medtronic plc
• Novartis AG
• SINOMED
• Smith & Nephew plc
• Teleflex Incorporated
• Teva Pharmaceutical Industries Ltd.
   

Drug Device Combination Products Industry News

• In April 2023, Teikoku Seiyaku Co., Ltd. and Kowa Company, Ltd. launched ALLYDONE patches (27.5 mg and 55 mg) for managing Alzheimer's-related dementia. Approved by the Ministry of Health, Labour and Welfare for slowing dementia symptoms progression, ALLYDONE patches were listed on the National Health Insurance (NHI) drug price standard, which significantly boosted the company's revenue.
   
• In August 2022, Medtronic plc launched the Onyx Frontier drug-eluting coronary stent (DES) following CE mark approval. The Onyx Frontier DES featured an innovative delivery mechanism and improved performance, building on the Resolute Onyx DES platform. The new stent offered enhanced deliverability and better acute performance, especially in complex clinical situations, thus benefiting the company by expanding its product portfolio.
   

This drug device combination products market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Billion from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Drug-eluting stents    
  • Coronary drug-elating stents
  • Peripheral drug-eluting stents
• Infusion pumps          
  • Implantable infusion pumps
  • Insulin infusion pumps
  • Patient-controlled analgesia pumps
  • Ambulatory infusion pumps
  • Volumetric infusion pumps
  • Disposable infusion pumps
• Photodynamic therapy         
• Wound care combination product  
• Prefilled syringes        
  • Single-chamber prefilled syringes
  • Dual-chamber prefilled syringes
  • Customized prefilled syringes
• Drug-eluting balloons            
  • Coronary drug-eluting balloons
  • Peripheral drug-eluting balloons
• Nebulizers     
• Inhalers           
  • Drug powdered inhalers (DPIs)
  • Metered dose inhalers (MDIs)
  • Soft mist inhalers (SMIs)
• Transdermal delivery systems           
  • Active transdermal systems
  • Passive transdermal systems
• Orthopedic combination products   
  • Bone graft implants
  • Antibiotic loaded bone cement
• Antimicrobial catheters         
  • Urological catheters
  • Cardiovascular catheters
  • Other catheters
  • Other products          

Market, By Application

• Cardiovascular disorders
• Diabetes
• Respiratory problems
• Cancer treatment
• Antimicrobial application
• Other applications

Market, By End-use

• Hospitals and clinics
• Ambulatory surgical centers
• Home care settings
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa